The Global Biotechnology Industry Outlook - 2024
Report Code: BT 8918 Dec, 2023, by marketsandmarkets.com
The global biotechnology industry outlook for 2024 once again confirms that the path to glory can only be possible with co-creation, collaboration and connectivity. In 2023, we witnessed companies increasingly focusing on co-creation of products and cut down on competition, collaborate in markets to counter the #1 player and reaching out to smaller towns and rural communities with services and solutions. Illumina is one of such companies that launched Global Health Access Initiative. There are many interesting journeys that Markets and Markets have captured for it’s audience.
The objective of this biotechnology industry outlook study is to
- To analyze the top disruptive technologies per region and how that impacts your business in 2024
- To understand regulatory changes, challenges and roadmap for your business in a market prone to recession and volatility
- To estimate the attractiveness of each region and identify the best opportunity that can help in market access and market expansion in 2024
- Understand the overall impact of digitization on biotechnology and if that can be a probable solution to cut down your operational and R&D cost, next year.
- To understand, evaluate the performance of biotechnology companies in 2023
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TABLE OF CONTENTS
STUDY COVERAGE
The study would include key details and insights regarding the trends and performance of Global Biotech Industry in 2024.
1 EXECUTIVE SUMMARY
1.1 TOP DEVELOPMENTS IN 2023
1.2 TOP DEVELOPMENTS EXPECTED IN 2024
2 RESEARCH SCOPE, OBJECTIVES AND METHODOLOGY
2.1 STUDY SCOPE
2.2 STUDY OBJECTIVES, METHODOLOGY, KEY INFORMATION AREAS
3 GLOBAL MACROECONOMIC ANALYSIS
3.1 GLOBAL AND REGIONAL MACRO-ECONOMIC ANALYSIS
4 TOP 10 TRENDS FOR 2024
4.1 FIRST EVER APPROVAL OF CRISPR, ADDS HOPE FOR MORE APPROVALS
4.2 APPROVED NUMBER OF CELL & GENE THERAPY EXPECTED TO RISE IN 2024
4.3 INVESTMENT IN BIOTECH INDUSTRY
4.4 BIOTECH M&A REMAIN HEALTHY AND EXPECTED TO RISE IN 2024
4.5 CELL THERAPY MANUFACTURING CAPACITY MAY FACE HURDLES
4.6 AI/ GEN AI CATCHES THE ATTENTION OF FIRST TIMERS AND ESTABLISHED PLAYERS TOGETHER
4.7 EFFORT TO SHORE UP DOMESTIC MANUFACTURING GROWS
4.8 PRICE HIKE ANTICIPATED THROUGHOUT THE YEAR EXCEPT FOR FEW SEGMENTS SUCH AS ONCOLOGY AND DIABETES
4.9 PHASE WISE CAPPING OF DRUGS IN US MARKET WILL LIMIT THE GROWTH OF BIG PLAYERS STARTING 2024
4.10 REAL WORLD EVIDENCE DATA (RWE) & TECH ENABLED DATA COLLECTION DEMAND GROWS IN CRO & BIOPHARMA R&D
5 GLOBAL BIOTECH INDUSTRY IN 2023
5.1 GLOBAL BIOTECH INDUSTRY PERFORMANCE: 2022 VS. 2023
5.1.1 BIOTECH INDUSTRY MARKET (USD BILLION), GLOBAL
5.1.2 BIOTECH INDUSTRY MARKET (USD BILLION), REGIONAL
5.1.3 GLOBAL BIOTECH RESEARCH AND DEVELOPMENT (USD BILLION), BY TYPE
5.1.4 GLOBAL BIOTECH RESEARCH AND DEVELOPMENT (USD BILLION), REGIONAL
5.1.5 GLOBAL BIOTECH MANUFACTURING (USD BILLION), BY TYPE
5.1.6 GLOBAL BIOTECH MANUFACTURING (USD BILLION), REGIONAL
5.1.7 GLOBAL BIOTECH THERAPY AND TREATMENT (USD BILLION), BY TYPE
5.1.8 GLOBAL BIOTECH THERAPY AND TREATMENT (USD BILLION), BY REGIONAL
5.2 KEY DEVELOPMENTS IN 2023
5.2.1 FIRST-TIME APPROVAL OF INNOVATIVE THERAPIES: TRANSFORMING TOMORROW WITH ALLOGENEIC CELL THERAPY, MICROBIOME MARVELS, AND CRISPR/CAS9
5.2.2 NEW REGULATIONS, SUCH AS THE FDA MODERNIZATION ACT 2.0, TO EXPEDITE ADOPTION OF ALTERNATIVE METHODS TO ANIMAL TESTING
5.2.3 RISING MOMENTUM: BIOTECH M&A SURGE IN 2023
5.2.4 GENE THERAPY APPROVALS 2023: TREATMENTS OFFER NEW HOPES FOR RARE DISEASES
5.2.5 CHINA REMAINED A CONFUSING MARKET FOR BIOPHARMA INDUSTRY WITH MANY BIG PLAYERS EXPECTING LOSSES DUE TO VOLUME-BASED PROCUREMENT (VBP)
5.2.6 REGULATORY BODIES BEGIN NEGOTIATING PRICES WITH DRUG MANUFACTURERS
5.2.7 AI COULD CUT DOWN THE COST AND TIMELINE IN DRUG DISCOVERY, MARKET RIDING ON A WAVE OF OPTIMISM
5.2.8 2023 WITNESSED THE PATENT EXPIRY OF TOP-SELLING BIOTECH DRUGS: BIOSIMILAR ENTRY WILL BOOM THE INDUSTRY AND BENEFIT PATIENTS
5.2.9 CAR-T CELL THERAPY APPROVALS RISING GLOBALLY
5.2.10 POST PANDEMIC CAPACITY CRUNCH IN CELL AND GENE MANUFACTURING FACILITY PUSHES MARKET TOWARDS INNOVATION
6 GLOBAL BIOTECH INDUSTRY OUTLOOK IN 2024
6.1 TOP BIOTECH INDUSTRY TRENDS FOR 2024
6.1.1 DEMAND FOR CRISPR-BASED GENE THERAPIES ON THE RISE
6.1.2 CELL AND GENE THERAPY APPROVALS WILL GAIN TRACTION
6.1.3 CAPACITY CRUNCH MAY LIMIT CELL AND GENE THERAPY MANUFACTURING SECTOR
6.1.4 BIOTECH INVESTMENT SURGE IN 2024
6.1.5 ANTICIPATING UPWARD TRENDS IN BIOTECH M&A AMIDST VOLATILITY
6.1.6 THE SURGE OF AI INNOVATION IN DRUG DISCOVERY
6.1.7 OFFSHORING AND DOMESTIC MANUFACTURING TO CONTINUE
6.1.8 BIOLOGICS CONTINUE TO ATTRACT STAKEHOLDERS
6.1.9 DRUG MANUFACTURERS IN THE US MAY FACE A TOUGH ROAD AHEAD
6.1.10 CRO & CDMO DEMANDS MORE REAL-WORLD EVIDENCE DATA (RWE)
6.2 GLOBAL BIOTECH INDUSTRY PERFORMANCE: 2023 VS. 2024
6.2.1 BIOTECH INDUSTRY MARKET (USD BILLION), GLOBAL
6.2.2 BIOTECH INDUSTRY MARKET (USD BILLION), REGIONAL
6.2.3 GLOBAL BIOTECH RESEARCH AND DEVELOPMENT (USD BILLION), BY TYPE
6.2.4 GLOBAL BIOTECH RESEARCH AND DEVELOPMENT (USD BILLION), REGIONAL
6.2.5 GLOBAL BIOTECH MANUFACTURING (USD BILLION), BY TYPE
6.2.6 GLOBAL BIOTECH MANUFACTURING (USD BILLION), REGIONAL
6.2.7 GLOBAL BIOTECH THERAPY AND TREATMENT (USD BILLION), BY TYPE
6.2.8 GLOBAL BIOTECH THERAPY AND TREATMENT (USD BILLION), BY REGIONAL
7 KEY GROWTH OPPORTUNITIES AND RECOMMENDATIONS
8 FINAL CONCLUSIONS AND TAKEAWAYS
9 APPENDIX
10 ABOUT MARKETSANDMARKETS
11 LEGAL DISCLAIMER
Request for detailed methodology, assumptions & how numbers were triangulated.
Growth opportunities and latent adjacency in The Global Biotechno